Garuda Therapeutics, a Cambridge, MA-based developer of durable blood stem cell-based cellular therapies, raised $62M in Series B funding.
The round, which brought the total amount of funding to $134M, was led by Northpond Ventures, OrbiMed Advisors, Cormorant Asset Management, and Aisling Capital, with participation from Sectoral Asset Management, Mass General Brigham Ventures, Alexandria Venture Investments. The company also announced the appointment of Raymond J. Kelleher, M.D., Ph.D., Managing Director at Cormorant Asset Management, to its Board of Directors.
The company intends to use the funds to further advance the development of its platform for generation of off-the-shelf, self-renewing blood stem cells towards the clinic as potential treatment for patients with hematological diseases, to continue the advancement of its proprietary HSC-derived off-the-shelf, durable immune cell program for treating patients with oncologic disorders, and advance continued development of HLA-matched pluripotent stem cells broadening the eligibility of patients and increasing access to blood and other cellular therapies in regenerative medicine.
Led by CEO Dhvanit Shah, Garuda Therapeutics provides a platform with a technology for generating off-the-shelf, self-renewing blood stem cells is poised to provide patients with rapid and broad access to consistent, durable, HLA-compatible and transgene-free blood stem cell therapies. Like bone marrow transplants, the technology could provide potentially curative therapies for more than 120 diseases.
FinSMEs
07/02/2023